Redcare Pharmacy Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Olaf Heinrich
Chief executive officer
€929.6k
Total compensation
| CEO salary percentage | 53.8% |
| CEO tenure | 1.7yrs |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 14
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Feb 27
eRx Surge And International Expansion Poised To Elevate Revenue And Profit Margins
Dec 30 Rapid expansion in new markets and tech-driven efficiencies suggest future revenue growth and improved profit margins.Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
Nov 11Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?
Apr 21Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?
Apr 07Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues
Mar 25Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt
Feb 13Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S
Dec 24Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?
Dec 06Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Sep 07Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching
Aug 02Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price
Jul 17Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher
May 28Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt
May 11We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt
Jan 10Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Sep 25Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?
Jun 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €930k | €500k | -€45m |
| Sep 30 2024 | n/a | n/a | -€25m |
| Jun 30 2024 | n/a | n/a | -€9m |
| Mar 31 2024 | n/a | n/a | -€10m |
| Dec 31 2023 | €569k | €208k | -€12m |
Compensation vs Market: Olaf's total compensation ($USD1.05M) is below average for companies of similar size in the German market ($USD2.50M).
Compensation vs Earnings: Olaf's compensation has increased whilst the company is unprofitable.
CEO
Olaf Heinrich (54 yo)
1.7yrs
Tenure
€929,606
Compensation
Mr. Olaf Heinrich is Chief Executive Officer and Member of the Managing Board at Redcare Pharmacy NV since August 01, 2023. Mr. Heinrich served as Member of the Management Board of “DocMorris” since 2008 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Member of the Managing Board | 1.7yrs | €929.61k | no data | |
| Co-Founder & Advisor | 1yr | €564.73k | no data | |
| Co-Founder & Advisor | 1yr | €564.73k | no data | |
| CFO & Member of Management Board | 5.2yrs | €839.87k | 0.013% € 332.2k | |
| COO & Member of the Managing Board | 9.3yrs | €827.34k | 0.74% € 18.4m | |
| Chief Commercial Officer & Member of Management Board | 1yr | €431.38k | 0.0093% € 232.0k | |
| Chief Information Officer & Member of Management Board | 1.3yrs | €441.76k | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| Chief Sales Officer | no data | no data | no data | |
| Director of Human Resources | no data | no data | no data | |
| Chief E-Health Officer | no data | no data | no data | |
| Chief Product Officer - Retail | no data | no data | no data |
1.3yrs
Average Tenure
51yo
Average Age
Experienced Management: RDC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 3yrs | €52.24k | no data | |
| Independent Member of Supervisory Board | 8.6yrs | €49.00k | 0.011% € 268.4k | |
| Independent Chairman of the Supervisory Board | 8.6yrs | €92.00k | no data | |
| Independent Deputy Chairman of Supervisory Board | 8.6yrs | €74.00k | 0.048% € 1.2m | |
| Independent Member of Supervisory Board | 4yrs | €57.00k | no data |
8.6yrs
Average Tenure
54yo
Average Age
Experienced Board: RDC's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 11:58 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Redcare Pharmacy NV is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Otto Sieber | Barclays |